This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

U.S. Sees Low Demand for BioCryst Flu Drug

BIRMINGHAM, Ala. ( TheStreet) -- As BioCryst Pharmaceuticals (BCRX) seeks to raise money from investors later this week, the U.S. government is seeing light demand so far for the company's antiviral flu drug peramivir.

With evidence emerging that H1N1 flu activity in the U.S. is peaking already, significant additional peramivir orders may not be needed.

A total of 829 treatment courses of peramivir have been shipped from the government's National Strategic Stockpile since the drug was made widely available on Oct. 23, according to Anita Patel, a health scientist working at the Centers for Disease Control and Prevention, the government agency in charge of distributing peramivir to doctors who request it as an emergency treatment for seriously ill H1N1 flu patients.

Patel disclosed the volume of peramivir shipments on a Nov. 13 conference call of the National Biodefense Science Board (NBSB), an advisory group under the auspices of the U.S. Department of Health and Human Services.

The 829 courses of peramivir were used to treat 533 patients, said Patel. Each course of peramivir includes enough drug to dose for five days, so some patients were treated with two courses, or 10 days, of peramivir.

"There's a total of 93% of our peramivir supply that remains, so we're confident that the current supply that we have will meet the demands as they've been set forth in the last couple of weeks," said Patel.

BioCryst sold 10,000 courses of peramivir to the U.S. government for $22.5 million on Nov. 5. Another 1,200 doses of the drug were donated. The drug, given intravenously, is still considered experimental and is not approved anywhere in the world.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs